Cure51

Is developing a therapeutic target discovery platform based on a proprietary clinical and multiomics database of patients who have survived aggressive cancers. By combining comparative multiomics analyses with artificial intelligence and computational modelling, Cure51 identifies unique biological signatures to design new targeted therapies and open up new perspectives in oncology.